Clinical Trials
20 trialsNCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03133221 2025-06-27
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
University of Maryland, Baltimore
Phase 2 Completed
NCT03890289 2024-11-21
GAUDEALIS
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT02962401 2023-08-29
RemodelWM3
French Innovative Leukemia Organisation
Phase 2 Completed
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT02968563 2022-01-21
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03576443 2021-10-13
ILIAD
Nordic Lymphoma Group
Phase 2 Completed
NCT01796470 2020-06-02
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 2 Terminated
NCT01282424 2019-07-11
DELTA
Gilead Sciences
Phase 2 Completed
NCT02258529 2019-05-14
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
Phase 2 Terminated
NCT01393106 2018-11-19
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Gilead Sciences
Phase 2 Completed
NCT02044822 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Gilead Sciences
Phase 2 Terminated
NCT01203930 2018-11-16
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Gilead Sciences
Phase 2 Terminated
NCT02662296 2017-09-27
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT02439138 2017-01-11
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01659047 2012-09-07
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 2 Withdrawn